RecruitingPhase 2NCT07507513

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of SSGJ-627 in Subjects With Moderate to Severe Active Ulcerative Colitis (UC)

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Enrollment

288 participants

Start Date

Mar 28, 2026

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis (UC)

Summary

This study will evaluate the efficacy and safety of 627 in patients with UC.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 627 and a drug called Placebo for people with ulcerative colitis (uc). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.